Phathom Pharmaceuticals, Inc.
PHAT
$4.41
$0.194.50%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 81.41% | 123.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 81.41% | 123.27% | |||
| Cost of Revenue | 61.93% | 71.22% | |||
| Gross Profit | 84.69% | 135.31% | |||
| SG&A Expenses | 0.77% | 0.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.22% | 2.98% | |||
| Operating Income | 16.07% | 8.41% | |||
| Income Before Tax | 13.00% | 6.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.00% | 6.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.00% | 6.42% | |||
| EBIT | 16.07% | 8.41% | |||
| EBITDA | 16.12% | 8.43% | |||
| EPS Basic | 20.87% | 15.20% | |||
| Normalized Basic EPS | 20.86% | 15.20% | |||
| EPS Diluted | 20.87% | 15.20% | |||
| Normalized Diluted EPS | 20.86% | 15.20% | |||
| Average Basic Shares Outstanding | 9.93% | 10.37% | |||
| Average Diluted Shares Outstanding | 9.93% | 10.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
